CONTENTS

ENVIRONMENTAL HEALTH CRITERIA ON PRINCIPLES AND METHODS FOR ASSESSING AUTOIMMUNITY ASSOCIATED WITH EXPOSURE TO CHEMICALS

PREAMBLE xi

ACRONYMS AND ABBREVIATIONS xxii

1. SUMMARY 1

2. INTRODUCTION AND DEFINITIONS OF AUTOIMMUNITY AND AUTOIMMUNE DISEASE 5

3. INTRODUCTION TO THE IMMUNE SYSTEM: FOCUS ON AUTOIMMUNE MECHANISMS 9

   3.1 Introduction 9
   3.2 The innate immune response 10
   3.3 The adaptive immune response 11
      3.3.1 Function 11
      3.3.2 Aberrant function 14
      3.3.3 Ageing 15
   3.4 Mechanisms of self-tolerance 16
   3.5 Immunopathogenesis of autoimmune disease 18
      3.5.1 Mechanisms of induction 18
      3.5.2 Effector mechanisms 21
   3.6 Summary 22

4. INTRINSIC FACTORS IN AUTOIMMUNITY 24

   4.1 Genetic factors involved in the induction of or susceptibility for autoimmune diseases 24
      4.1.1 Probable monogenic autoimmune syndromes 24
      4.1.2 Multigenic autoimmune diseases 26
         4.1.2.1 Immune deficiencies 27

4.1.2.2 Defects and dysregulation in apoptosis pathways and cell cycle regulation 29
4.1.2.3 Associations with MHC alleles or haplotypes 31
4.1.2.4 Polymorphisms in genes coding for regulatory and effector molecules of the immune system 35
4.1.2.5 Hormones and genes 37
4.1.2.6 Genetic polymorphisms of xenobiotic-metabolizing enzymes 38
4.1.2.7 Genes coding for autoantigens 39
4.1.2.8 Genes coding for enzymes involved in post-translational modification of autoantigens 40
4.1.2.9 DNA methylation 41
4.1.3 Problems and perspectives 41
4.2 Hormonal influence on autoimmunity 42
4.2.1 Pregnancy 42
4.2.1.1 Suppression of autoimmunity 42
4.2.1.2 Stimulation of autoimmunity 43
4.2.2 Psychological stress 46

5. CLINICAL EXPRESSION OF HUMAN AUTOIMMUNE DISEASES 47

5.1 Introduction 47
5.2 Addison disease 50
5.3 ANCA-associated vasculitis 51
5.4 Antiphospholipid syndrome 52
5.5 Coeliac disease 53
5.6 Diabetes mellitus 54
5.7 Goodpasture disease 55
5.8 Guillain-Barré syndrome 56
5.9 Autoimmune haemolytic anaemia 57
5.9.1 Warm autoimmune haemolytic anaemia 57
5.9.2 Cold autoimmune haemolytic anaemia 58
5.9.3 Drug-induced autoimmune haemolytic anaemia 59
5.10 Autoimmune hepatitis 59
5.11 Inflammatory bowel disease 61
5.11.1 Crohn disease 61

	5.11.2 Ulcerative colitis	62
5.12	Multiple sclerosis	63
5.13	Myasthenia gravis	64
5.14	Myocarditis	66
5.15	Autoimmune myositis	66
5.16	Paraneoplastic neurological syndromes	67
5.17	Pemphigus/pemphigoid	68
	5.17.1 Pemphigus	69
	5.17.2 Pemphigoid	70
5.18	Pernicious anaemia	70
5.19	Autoimmune polyglandular syndromes	71
	5.19.1 APGS type 1	71
	5.19.2 APGS type 2	72
	5.19.3 APGS type 3	72
5.20	Primary biliary cirrhosis	72
5.21	Psoriasis	73
5.22	Rheumatoid arthritis	74
5.23	Scleroderma (systemic sclerosis)	75
5.24	Sjögren syndrome	77
5.25	Systemic lupus erythematosus and lupus syndrome	78
	5.25.1 Systemic lupus erythematosus	78
	5.25.2 Lupus syndrome	79
5.26	Autoimmune thrombocytopenia	80
	5.26.1 Immune thrombocytopenic purpura	80
	5.26.2 Thrombotic thrombocytopenic purpura	81
	5.26.3 Drug-induced thrombocytopenia	81
5.27	Autoimmune thyroid diseases	82
	5.27.1 Graves disease	83
	5.27.2 Hashimoto thyroiditis	83
	5.27.3 Iodine and thyroid disease	84
5.28	Diseases with autoimmune components	85
6.	EPIDEMIOLOGY	87
6.1	Descriptive epidemiology	87
	6.1.1 Demographic patterns	89
	6.1.2 Co-morbidity of autoimmune diseases	91
6.2	Epidemiology of autoantibodies	92
	6.2.1 Prevalence of autoantibodies in the general population	92

6.2.2 Associations between antibodies and environmental exposures 94

7. MECHANISMS OF CHEMICAL-ASSOCIATED AUTOIMMUNE RESPONSES 96

7.1 General 96
7.2 Induction of antigen-specific responses 98
7.2.1 Formation of neoantigens 98
7.2.2 Cross-reactivity 99
7.2.3 Release of non-tolerant epitopes 100
7.2.4 Interference with central tolerance 101
7.2.5 Signal 2 increasing mechanisms 102
7.2.5.1 Importance of signal 2 102
7.2.5.2 Induction of signal 2 103
7.2.6 Immunoregulation 104
7.3 Other mechanisms 106

8. CHEMICAL/PHYSICAL AGENTS AND AUTOIMMUNITY 107

8.1 Toxic oil syndrome 107
8.1.1 Clinical features of toxic oil syndrome 108
8.1.2 Immune markers in toxic oil syndrome 109
8.1.3 Experimental studies of toxic oil syndrome 111
8.2 TCDD (dioxins) 114
8.3 Pesticides 115
8.3.1 General 115
8.3.2 Hexachlorobenzene 117
8.3.2.1 Accidental poisoning in Turkey 118
8.3.2.2 Adverse immune effects of hexachlorobenzene 118
8.4 Ultraviolet radiation 122
8.5 Silica 122
8.5.1 Introduction to epidemiological studies of silica exposure 122
8.5.2 Occupational silica exposure and systemic autoimmune diseases 124
8.5.3 Experimental studies of immune- and autoimmune-related effects of silica 127
8.5.4 Summary 130
8.6 Heavy metals 131

8.6.1 Mercury 131
8.6.2 Gold 135
8.6.3 Cadmium 135
8.6.4 Other heavy metals 136
8.7 Solvents 138
8.8 Tobacco smoke 141
8.9 Ethanol 145
8.10 Iodine 148
8.11 Therapeutic agents 149
8.11.1 General 149
8.11.2 Hydralazine 150
8.11.3 Procainamide 151
8.11.4 D-Penicillamine 152
8.11.5 Zimeldine 153
8.11.6 Gold drugs 153
8.11.7 Biopharmaceuticals 155
8.11.8 Diethylstilbestrol 156
8.11.8.1 Diethylstilbestrol-induced immune alterations 156
8.11.8.2 Immune effects of diethylstilbestrol in humans 157
8.11.8.3 Conclusion 159
8.12 Silicones 159
8.12.1 Introduction 159
8.12.2 Silicone breast implants and systemic disease 160
8.12.3 Conclusion 162

9. NON-CHEMICAL FACTORS IN AUTOIMMUNITY 163

9.1 Infections: cause of autoimmunity, and immune programming 163
9.1.1 Streptococcus and rheumatic fever 165
9.1.2 Hepatitis C virus 166
9.1.3 Epstein-Barr virus 167
9.1.4 Other infections 167
9.1.5 Absence of infections: the hygiene hypothesis 168
9.2 Vaccine-related factors 169
9.2.1 Vaccines themselves 169
9.2.2 Vaccine additives 170
9.3 Dietary factors 171
9.3.1 Caloric restriction and leptin 172

9.3.2 Dietary fat and fatty acid content 172
9.3.3 Antioxidants 174
9.3.4 Vitamin D 174
9.3.5 L-Tryptophan and eosinophilia myalgia syndrome 175

10. ANIMAL MODELS TO ASSESS CHEMICAL-INDUCED AUTOIMMUNITY 178

10.1 Introduction 178
10.2 Rat models 180
10.2.1 The Brown Norway rat model 180
10.2.1.1 Metals 181
10.2.1.2 D-Penicillamine 182
10.2.1.3 Hexachlorobenzene 182
10.2.2 Other rat models 183
10.3 Mouse models 183
10.3.1 Metals 184
10.3.2 Drugs 184
10.3.3 Pristane 185
10.4 Genetically predisposed animal models 186
10.4.1 Systemic lupus erythematosus-prone strains of mice 186
10.5 Other species 187
10.6 Local and popliteal lymph node assays 188
10.6.1 Introduction 188
10.6.2 Primary, secondary, and adoptive popliteal lymph node assays and the lymph node proliferation assay 188
10.6.3 Reporter antigen popliteal lymph node assay 189
10.6.4 Popliteal lymph node assay as predictive assay 191
10.7 Testing strategy 191

11. HUMAN TESTING FOR AUTOIMMUNE DISEASE 193

11.1 Introduction 193
11.2 Methods of human autoantibody detection 195
11.2.1 Indirect immunofluorescence technique 195
11.2.2 Counter-immunoelectrophoresis 195
11.2.3 Haemagglutination 196

11.2.4 Enzyme-linked immunosorbent assay/ fluorescent enzyme immunoassay 197
11.2.5 Radioimmunoassay 198
11.2.6 Immunoblotting 199
11.2.7 Multiplex analysis 199
11.3 Selection of detection method 200
11.3.1 Autoantigens 200
11.3.2 Anti-immunoglobulin reagents 202
11.4 Clinical interpretation 203
11.5 Human immunoglobulins 204
11.5.1 Autoimmune disease and human immunoglobulin levels 204
11.5.2 Quantification of human immunoglobulins 205
11.6 Testing in the diagnosis of delayed-type chemical hypersensitivity 207
11.7 Conclusions 208

12. RISK ASSESSMENT 211

12.1 Introduction 211
12.2 Hazard identification of chemical-induced autoimmune disease (animal models) 212
12.3 Exposure assessment (animal models) 213
12.4 Mode of action 213
12.5 Epidemiological issues 215
12.6 Susceptibility factors 216
12.7 Burden of autoimmune disease 217

13. CONCLUSIONS AND RECOMMENDATIONS 219

13.1 Conclusions 219
13.2 Recommendations 220

TERMINOLOGY 222

REFERENCES 256

RESUME 325

RESUMEN 330